Role of Dexamethasone in Transversus Abdominis Plane Block After Cesarean Section
- Conditions
- Cesarean Section
- Interventions
- Registration Number
- NCT03767920
- Lead Sponsor
- Aswan University Hospital
- Brief Summary
Our aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone in transversus abdominis plane (TAP) block for postoperative analgesia in patients undergoing an elective Caesarean section.
* Group 1: bupivacaine 0.25% + dexamethasone 8 mg
* Group 2: bupivacaine 0.25% A prospective Randomized Interventional double-blind study.
- Detailed Description
The pain and discomfort following cesarean delivery are mostly due to the abdominal wall incision and dissection of muscles; it delays early ambulation and breastfeeding. This can lead to postoperative complications such as thromboembolic disorders. So, providing an effective and safe postoperative analgesic method seems to be mandatory. Opioid analgesia remains the most effective means of relieving pain in a wide variety of conditions; however, it may cause adverse effects such as nausea, vomiting, pruritus, urinary retention, and respiratory depression. As the analgesia and the side effects of opioids are dose-dependent, a multimodal approach may enhance analgesia, which in turn would decrease the side effects .
Mc Donnell and colleagues have reported that a transversus abdominis plane (TAP) block can decrease the postoperative pain following abdominal surgery. The landmarks of this block were first described in 2001 by Rafi. The TAP block has been performed for postoperative analgesic control in patients undergoing radical prostatectomy, hysterectomy, cesarean delivery under spinal anesthesia, and laparoscopic surgery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 120
- healthy parturient (ASA I and II) scheduled to undergo LSCS under spinal anesthesia
- Participants had known sensitivity to bupivacaine
- patient refusal,
- localized infection over injection point
- patients with significant coagulopathies and
- with contraindications to regional anesthesia,
- patients with heart diseases, altered renal or liver functions,
- psychological disorders, patients with pregnancy-induced hypertension and
- gestational diabetes, chronic use of pain medications,
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description bupivacaine and placebo to dexamethasone placebo to dexamethasone BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone bupivacaine and placebo to dexamethasone bupivacaine BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone bupivacaine and dexamethasone bupivacaine Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline. bupivacaine and dexamethasone dexamethasone Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
- Primary Outcome Measures
Name Time Method Visual analog score for pain during movement 6 hours post operative movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain
- Secondary Outcome Measures
Name Time Method number of patients need Fentanyl consumption 48 hours postoperative number of patients need Fentanyl consumption
number of days patients stay in hospital 4 weeks calculation of number of days patients stay in hospital
Visual analog score during rest 48 hours postoperative ranging from 0 to 10, where 0 no pain and 10 maximum pain
Trial Locations
- Locations (1)
Aswan University
🇪🇬Aswan, Egypt